Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;11(3):817-828.
doi: 10.1007/s40744-024-00652-7. Epub 2024 Mar 6.

Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison

Philip J Mease  1 , Richard B Warren  2 , Peter Nash  3 , Jean-Marie Grouin  4 , Nikos Lyris  5 , Damon Willems  6 , Vanessa Taieb  7 , Jason Eells  5 , Iain B McInnes  8
Affiliations

Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison

Philip J Mease et al. Rheumatol Ther. 2024 Jun.

Abstract

Introduction: Matching-adjusted indirect comparisons (MAICs) were used to compare the efficacy of bimekizumab and secukinumab 150 mg and 300 mg at 52 weeks for the treatment of psoriatic arthritis (PsA) in patients who were biologic disease-modifying anti-rheumatic drug-naïve (bDMARD-naïve) or with previous inadequate response or intolerance to tumor necrosis factor inhibitors (TNFi-IR).

Methods: Relevant trials were systematically identified. Individual patient data from bimekizumab randomized controlled trials, BE OPTIMAL (N = 431) and BE COMPLETE (N = 267), were matched to aggregate data from bDMARD-naïve and TNFi-IR patient subgroups from FUTURE 2 using secukinumab 150 mg and 300 mg doses (bDMARD-naïve: N = 63/37; TNFi-IR: N = 67/33). To adjust for cross-trial differences, patients from the bimekizumab trials were re-weighted using propensity scores to match the baseline characteristics of patients in the secukinumab trials. Unanchored comparisons of recalculated bimekizumab and secukinumab 52-week non-responder imputation outcomes for 20/50/70% improvement in American College of Rheumatology score (ACR20/50/70) and minimal disease activity (MDA) index were analyzed.

Results: In patients who were bDMARD-naïve, bimekizumab had a greater likelihood of ACR70 response than secukinumab 150 mg (odds ratio [95% confidence interval] 2.39 [1.26, 4.53]; p = 0.008) and secukinumab 300 mg (2.03 [1.11, 3.72]; p = 0.021) at 52 weeks. In patients who were TNFi-IR, bimekizumab had a greater likelihood of response compared to secukinumab 150 mg for ACR20 (3.50 [1.64-7.49]; p = 0.001), ACR50 (3.32 [1.41, 7.80]; p = 0.006), ACR70 (2.95 [1.08, 8.07]; p = 0.035) and MDA (3.52 [1.38, 8.99]; p = 0.009), and a greater likelihood of response compared to secukinumab 300 mg for ACR50 (2.44 [1.06, 5.65]; p = 0.037) and MDA (2.92 [1.20, 7.09]; p = 0.018) at 52 weeks.

Conclusion: In this MAIC analysis, the efficacy of bimekizumab, as demonstrated by the likelihood of ACR20/50/70 and MDA response at 52 weeks, was greater or comparable to secukinumab 150 mg and 300 mg for patients with PsA who were bDMARD-naïve and TNFi-IR.

Trial registration numbers: NCT03895203, NCT03896581, NCT04009499, NCT01752634, NCT01989468, NCT02294227, NCT02404350.

PubMed Disclaimer

Conflict of interest statement

Philip J. Mease: Research grants from AbbVie, Acelyrin, Amgen, BMS, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Sun Pharma and UCB Pharma; consultancy fees from AbbVie, Acelyrin, Aclaris, Alumis, Amgen, BMS, Boehringer Ingelheim, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Moonlake Pharma, Novartis, Pfizer, Sun Pharma, Takeda, and UCB, and Ventyx Pharma; speakers’ bureau from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB Pharma. Richard B. Warren: Supported by the Manchester NIHR Biomedical Research Centre; consulting fees from AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, GSK, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB Pharma; research grants to his institution from AbbVie, Almirall, Janssen, LEO Pharma, Novartis, and UCB Pharma; and honoraria from Astellas, DiCE, GSK, and Union. Peter Nash: Research grants, clinical trials and honoraria for advice and lectures on behalf of AbbVie, Boehringer Ingelheim, BMS, Eli Lilly, Galapagos/Gilead, GSK, Janssen, Novartis, Pfizer, Samsung, Sanofi, and UCB Pharma. Jean-Marie Grouin: Consulting fees and honoraria from Acticor, Chugai, BeiGene, Inflectis, Inotrem, Ipsen, Janssen, Otsuka, SpikImm, UCB Pharma. Damon Willems, Nikos Lyris, Jason Eells, Vanessa Taieb: Employee and stockholder of UCB Pharma. Iain B. McInnes: Consulting fees and honoraria from AbbVie, AstraZeneca, BMS, Boehringer Ingelheim, Cabaletta, Causeway Therapeutics, Celgene, Evelo, Janssen, Novartis, Lilly, Moonlake, and UCB Pharma; and research support from BMS, Boehringer Ingelheim, Celgene, Janssen, Novartis, and UCB Pharma.

Figures

Fig. 1
Fig. 1
Summary of MAIC matching. Note: MAICs use IPD from trials of one treatment to match baseline aggregate statistics reported from trials of another treatment. Using propensity score weighting techniques to balance trial population characteristics, indirect comparisons can be made. Trial populations adjusted for age, sex, MTX use, HAQ-DI, BSA ≥ 3%, SJC, and TJC. bDMARD biologic disease-modifying anti-rheumatic drug-naïve, BSA body surface area, ESS effective sample size, HAQ-DI Health Assessment Questionnaire–Disability Index, IPD individual patient data, MAIC matching-adjusted indirect comparison, MTX methotrexate, Q4W every 4 weeks, Q8W every 8 weeks, SEC secukinumab, SJC swollen joint count, TJC tender joint count, TNFi-IR tumor necrosis factor inhibitor-inadequate response or intolerant
Fig. 2
Fig. 2
Matching-adjusted odds ratio comparison of bimekizumab vs secukinumab (150 mg and 300 mg) at week 52 (NRI). a BKZ 160 mg Q4W vs SEC 150 mg Q4W in patients with PsA who were bDMARD-naïve, b BKZ 160 mg Q4W vs SEC 300 mg Q4W in patients with PsA who were bDMARD-naïve, c BKZ 160 mg Q4W vs SEC 150 mg Q4W in patients with PsA who were TNFi-IR, d BKZ 160 mg Q4W vs SEC 300 mg Q4W in patients with PsA who were TNFi-IR. *Indicates statistical significance. Figure shows a logarithmic scale. ACR American College of Rheumatology, ACR20/50/70 at least a 20/50/70% improvement according to the ACR response criteria, bDMARD biologic disease-modifying anti-rheumatic drugs, BKZ bimekizumab, CI confidence interval, ESS effective sample size, MDA minimal disease activity, NRI non-responder imputation, OR odds ratio, PsA psoriatic arthritis, pts patients, Q4W every 4 weeks, SEC secukinumab, TNFi-IR tumor necrosis factor inhibitor-inadequate response or intolerant
Fig. 3
Fig. 3
Sensitivity analysis of MAIC using pooled data from FUTURE 2–5 RCTs for secukinumab. a BKZ 160 mg Q4W vs SEC 150 mg Q4W in patients with PsA who were bDMARD-naïve, b BKZ 160 mg Q4W vs SEC 300 mg Q4W in patients with PsA who were bDMARD-naïve, c BKZ 160 mg Q4W vs SEC 150 mg Q4W in patients with PsA who were TNFi-IR, d BKZ 160 mg Q4W vs SEC 300 mg Q4W in patients with PsA who were TNFi-IR. *Indicates statistical significance. Figure shows a logarithmic scale. ACR American College of Rheumatology, ACR20/50/70 at least a 20/50/70% improvement according to the ACR response criteria, bDMARD biologic disease-modifying anti-rheumatic drugs, BKZ bimekizumab, CI confidence interval, ESS effective sample size, MAIC matching-adjusted indirect comparison, NRI non-responder imputation, OR odds ratio, pts patients, Q4W every 4 weeks, SEC secukinumab, TNFi-IR tumor necrosis factor inhibitor-inadequate response or intolerant
See this image and copyright information in PMC

References

    1. Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729–735. doi: 10.1016/j.jaad.2013.07.023. - DOI - PubMed
    1. Wang EA, Suzuki E, Maverakis E, Adamopoulos IE. Targeting IL-17 in psoriatic arthritis. Eur J Rheumatol. 2017;4(4):272–277. doi: 10.5152/eurjrheum.2017.17037. - DOI - PMC - PubMed
    1. Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329–1339. doi: 10.1056/NEJMoa1412679. - DOI - PubMed
    1. Kavanaugh A, McInnes IB, Mease PJ, et al. Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study. J Rheumatol. 2016;43(9):1713–1717. doi: 10.3899/jrheum.160275. - DOI - PubMed
    1. Nash P, Mease PJ, McInnes IB, et al. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3) Arthritis Res Ther. 2018;20(1):47. doi: 10.1186/s13075-018-1551-x. - DOI - PMC - PubMed

Associated data